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Patientswithchronicobstructivepulmonarydisease(COPD)areatincreasedriskforosteoporosisandfracturesbecauseoflifestyle
factors, systemic eﬀects of the disease, side eﬀects of treatment, and comorbidities. The initial evaluation of COPD men for
osteoporosis must include a detailed medical history and physical examination, assessment of COPD severity, and additional
tests, as suggested by results of clinical evaluation. Osteoporosis is diagnosed on the basis of bone mineral density (BMD)
measurement with DEXA of the lumbar spine and hip, but fracture risk assessments tools, as FRAX, could be used as useful
supplements to BMD assessments for therapeutics interventions. The prevention and treatment of osteoporosis in COPD involves
nonpharmacologic and pharmacologic measures, as lifestyle measures and nutritional recommendations, management of COPD
treatment (based on the use of limited corticosteroids doses), and drug therapy (bisphosphonates, teriparatide). In this paper, the
current recommendations for diagnosis and management of osteoporosis in COPD men, based on recent medical bibliography,
are presented and discussed.
1.Introduction
Chronic obstructive pulmonary disease (COPD) is a major
causeofmorbidity andmortality worldwideandasecondary
cause of bone loss [1–3]. It is characterised by a progressive
airﬂow limitation that is not fully reversible and develops as
a consequence of genetic susceptibility, increasing life span,
environmental, and lifestyle factors [1, 3, 4]. The degree
of airﬂow limitation can be assessed by spirometry and
stratiﬁedinaccordancewiththeGlobalInitiativeforChronic
Obstructive Pulmonary Disease (GOLD) [4]. Osteoporosis
is a common systemic skeletal disease characterised by
low bone mass with microarchitectural disruption and
skeletal fragility, resulting in an increased risk of fracture,
most commonly at the spine, hip, or wrist and causing
signiﬁcant morbidity and mortality [3, 5]. Osteoporosis in
men continues to be underdiagnosed and untreated due to
the rather exclusive focus on postmenopausal osteoporosis
in the past; corticosteroid use, excessive alcohol use, and
hypogonadismwhicharethemostfrequentsecondarycauses
of male osteoporosis [2, 6]. Although osteoporosis is less
prevalent in men, it has been estimated that 30% of all
h i pf r a c t u r e so c c u ri nm a l e sa n dt h a to n ei ne i g h tm e n
older than 50 years will experience an osteoporotic fracture
[5]. Moreover, many studies have shown that osteoporotic
fractures are associated with greater morbidity and mortality
in men compared with women [5, 7].
The majority of COPD patients in clinical practice are
men of older age with many underdiagnosed additional
risk factors for osteoporosis. The purpose of this paper is
to review the current recommendations for diagnosis and
management of osteoporosis in COPD men.
2. Pathogenesis andPrevalence of
Osteoporosis in COPD
PatientswithCOPDareatincreasedriskforosteoporosisand
fractures because of lifestyle factors, systemic eﬀects of the
disease, side eﬀects of treatment, and comorbidities [1, 8]. It
is marked that COPD and osteoporosis share some common2 ISRN Rheumatology
risk factors [8]. The current or past tobacco smoking, the
inactivity,andweightloss(knownaspulmonarycachexia)in
COPD patients are associated with decreased bone mineral
density (BMD) and increased risk of fractures [1]. Also,
COPD itself is an independent predictor of BMD reduction
and vertebral fracture risk, and increasing disease severity
increases the risk for osteoporosis and fracture risk [1, 3, 9].
It could be explained, as a result of mediators, inﬂam-
matory cytokines (interleukin [Il]-6, TNF-α) which induce
expression of RANKL (receptor activator of nuclear factor-
κB ligand) and RANKL-mediated bone resorption [10]. In
addition, many other cytokines have been found to interact
with the OPG (osteoprotegerin)/RANKL system, supporting
the concept that inﬂammatory mediators contribute to
the regulation of bone remodelling [10]. Moreover, COPD
patients, as well as patients with other chronic diseases,
often have deﬁcient calcium (Ca) and vitamin D nutritional
status, and the latter is frequently accentuated because of
little exposure to sunlight [1, 10]. Among available treat-
ments for COPD, only corticosteroid- (CS-) treatment has
documented adverse eﬀects of clinical signiﬁcance [1, 10].
Oral glucocorticosteroids (OGCS) have both direct adverse
eﬀects on bone and indirect eﬀects due to muscle weakening
andatrophy.Theseeﬀectsaredosedependentbothregarding
daily dose, duration, and cumulative dose. Less negative
eﬀects are seen by sporadic compared to continuous use,
but lower continuous doses have less detrimental eﬀects on
bone than frequent high-dose course of OGCS [1]. Systemic
OGCScancausearapidbonelosswithintheﬁrstfewmonths
of treatment, followed by a slower 2–5% loss per year with
chronicuse[11].However,OGCSarerecommendedonlyfor
7 to 10 days with 30 to 40mg prednisolone in exacerbations
in patients with severe COPD; long-term treatment with
OGCS is not recommended in COPD [12]. High doses of
inhaled corticosteroids (ICS) seem to increase bone loss, but
the extent of this eﬀect is discussed because it is diﬃcult
to diﬀerentiate between the eﬀect of ICS dose used, other
risk factors, prior or concomitant use of OGCS, and not
at least, disease severity [1]. A recent study, addressing
static and dynamic indices of cancellous and cortical bone
structure in postmenopausal women with COPD who had
notreceivedchronicOGCS,revealedskeletalmicrostructural
abnormalities in cancellous and cortical bone providing an
explanation for the high prevalence of vertebral fractures
in this disease [13]. It is important to prevent fractures in
COPD patients, considering that hip and vertebral fractures
mightimpairmobility,andvertebralfracturesfurtherreduce
lung function decreasing the forced vital capacity (FVC),
such as the increased operative risk and risk of death of these
patients following osteoporotic hip fractures [1, 3, 14].
Theprevalenceofosteoporosis andosteopenia (lowbone
mass) in COPD patients varies between 9–69% and 27–67%,
respectively, depending on the diagnostic methods used,
the population studied, and the severity of the underlying
respiratory disease [3]. In COPD patients, the prevalence of
osteoporosis is assumed to be two- to ﬁvefold higher than
thatinage-matchedsubjectswithoutairﬂowobstruction[3].
In a recently developed screening tool for males at risk for
Table 1: Factors independent of bone mineral density that increase
fracture risk in men [2].
(A) Primary factors
(i) Previous fragility fracture after 40 years of age, especially
vertebral compression fractures∗
(ii) Systemic glucocorticoid therapy+ of ≥3 months’ duration
(iii) Advancing age, especially past 65yr
(B) Other key factors
(i) Presence of disease or a condition associated with bone loss
(ii) Family history of osteoporotic fracture
(iii) High alcohol intake: >2 units (i.e., >18g) of alcohol daily
(iv) Hypogonadism, primary or secondary
(v) Low BMI (<20kg/m2) associated with bone loss
(vi) Smoking, current or past
(vii) Use of LHRH analogs (antiandrogen therapy)
LHRH: luteinizing hormone–releasing hormone, BMI: body mass index.
∗Height loss of ≥6cm or kyphosis may be a clinical sign of a vertebral
compression fracture;
+The equivalent of ≥7.5mg/d of prednisone.
osteoporosis, the presence of COPD is one of the parameters
increasing this risk almost four times [15].
3.DiagnosisofMaleOsteoporosis and
the Role of Bone Densitometry
The initial evaluation of COPD men for osteoporosis must
include a detailed medical history and physical examination
to identify important clinical risk factors that may contribute
to bone loss or increase fracture risk in men (Table 1)a n d
to exclude other, except COPD, secondary causes of bone
loss in men (Table 2)[ 2, 6]. Assessment of COPD severity
is necessary based on the patient’s level of symptoms, the
severity of the spirometric abnormality (Table 3), and the
presence of complications such as respiratory failure, right
heart failure, weight loss, and arterial hypoxemia [4, 12].
Assessment of serum 25-hydroxy vitamin D (25-OHD),
such as other additional tests, as suggested by results of
clinical evaluation, should be performed (Table 4)[ 2, 6].
Men should have their height measured at baseline and at
serialassessments,becauseheightlossmayreﬂectunderlying
vertebral compression fractures that are often clinically
silent [1, 2, 6]. Patients with back pain, height loss, or
kyphosis should undergo lateral spinal radiography to detect
the presence of vertebral fractures [2, 6]. The presence of
vertebral deformities, clinical vertebral fractures, and other
types of bone fracture (pelvis, humerus, ribs, etc.) not
associated with important traumas is always suspicious and
should lead to a more speciﬁc study of the bone status.
Among the intrinsic skeletal factors, low BMD has been
consistently associated with an increase in bone fractures.
BMD measurement with dual energy X-ray absorptiometry
(DEXA) is the accepted reference standard for diagnosis of
osteoporosis in men with COPD [1, 2, 16, 17]. Considering
that COPD is a secondary cause of osteoporosis, it is
suggested that COPD men with 3 minor (BMI < 21kg/m2,ISRN Rheumatology 3
Table 2: Secondary causes of bone loss in men [2, 6].
Common Less Common
Cushing’s syndrome or corticosteroid therapy
(e.g., >5mg/dayfor>3m o n t h s )
Low BMI (<20Kg/m2) and eating disorders associated with decreased BMI
Lack of exercise or excessive exercise
Excessive alcohol use Antiepileptic drugs (phenytoin, phenobarbitone, primidone, carbamazepine)
Primary or secondary hypogonadism
Low calcium intake and vitamin D deﬁciency Thyrotoxicosis or thyroxine overreplacement
Smoking Primary hyperparathyroidism
Family history of minimal trauma fracture Chronic liver or kidney disease
Malabsorption, including celiac disease
Chronic lung disease Hypercalciuria
Rheumatoid arthritis or ankylosing spondylitis
Type 1 or type 2 diabetes mellitus
Multiple myeloma or other monoclonal gammopathies
HIV or its treatment with protease inhibitors
Mastocytosis
Organ transplantation or immunosuppressive agents (cyclosporine and tacrolimus)
Osteogenesis imperfecta
BMI: body mass index (deﬁned as the weight in kilograms divided by the square of the height in meters).
Table 3: Spirometric classiﬁcation of chronic obstructive pulmonary disease severity based on postbronchodilator FEV1 [4, 11].
Stage I: mild FEV1/FVC < 0.70 FEV1  80% predicted
Stage II: moderate FEV1/FVC < 0.70 50%  FEV1 < 80% predicted
Stage III: severe FEV1/FVC < 0.70 30%  FEV1 <50% predicted
Stage IV: very severe FEV1/FVC < 0.70 FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failure∗
FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity
∗Respiratory failure: arterial partial pressure of oxygen (Pao2) <8.0kPa (60mm Hg) with or without arterial partial pressure of CO2(Paco2) >6.7kP a(50mm
Hg) while breathing air at sea level.
current smoking, use of ethanol >3units/day, age > 65 years,
parent hip fracture, rib fracture, inactivity, FEV1 < 50% pre-
dicted)or1major[systemiccorticosteroids(3months/year),
major fragility fracture (spine-hip)] criteria are at increased
riskforosteoporosisandthereforecandidatesforDEXA[10].
The bone densitometry deﬁnition of osteoporosis in men is
not as well-standardised as it is in postmenopausal women
[18]. However, as in women, BMD measurements, given as
area density, but also as T-scores [standard deviations (SD)
compared with young adult sex-matched controls] and Z-
scores (compared with age-and sex-matched controls), are
useful for predicting osteoporotic fractures in men [19, 20].
For every standard deviation (SD) reduction in BMD at the
spine or hip, men have a relative risk of fracture that is
similar to, or even greater than, the relative risk in women.
In contrast, the age-speciﬁc prevalence of osteoporosis and
fracture is lower in men than in women, and therefore,
men have a lower absolute risk for fracture than women
at any bone density T-score [20]. Based upon the similar
relationship between BMD and fracture in men and women,
the World Health Organization (WHO) recommends using
the same classiﬁcation of BMD to deﬁne osteoporosis in
men (age 50 and older) as in women [21]. The WHO has
deﬁnedosteopenia(lowbonemass)asBMDT-scorebetween
−1.0 and −2.5 SD and osteoporosis as T-score ≤− 2.5 SD
[22].
In COPD men, DEXA measurements of the lumbar
spine and hip are suggested, because fractures at these
sites have the greatest impact on patients’ health [1, 17].
DEXA measurement at these two levels, together with the
investigation of vertebral deformities using a spine X-ray,
has been the techniques most used in clinical trials and in
all types of studies on osteoporosis. They are also the most
important tools to evaluate the eﬃcacy of antiosteoporotic
drugs. Measurement of hip BMD also has the highest pre-
dictive value for hip fracture. In addition, if pharmacologic
therapy is planned, measurement of lumbar spine BMD is
useful as it shows less variability and can detect responses
to therapy earlier than hip BMD. We make the diagnosis
of osteoporosis based on the lowest T-score measured of
either the spine or the hip. Interference from osteophytes
and vascular calciﬁcations on the spine measurement are4 ISRN Rheumatology
Table 4:Laboratorytestsfortheassessmentofmenwithosteoporo-
sis [2, 6].
(A) Tests to exclude secondary causes of bone loss
(i) Complete blood count
(ii) Serum calcium
(iii) Albumin
(iv) Liver transaminases
(v) Serum creatinine and calculated creatinine clearance
(vi) Alkaline phosphatise
(vii) Thyroid-stimulating hormone (TSH)
(viii) Testosterone-total, as well as free or bioavailable
(B) Additional tests, as suggested by results of clinical
evaluation
(i) Parathyroid hormone (PTH)
(ii) Serum 25-hydroxy vitamin D (25-OHD)
(iii) Serum immunoelectrophoresis
(iv) Celiac antibody testing: gliadin, endomyseal, tissue
transglutaminase
(v) 24-hour urine: calcium
(vi) 24-hour urine: free cortisol
c o m m o ni na g i n gm e n( a f t e rt h ea g eo f6 0t o6 5y e a r s )
and interfere with the assessment of BMD at this site
(artiﬁcially high values of BMD in the anterior-posterior
directed measurements). In this setting, measurement of
hip BMD alone is suﬃcient. Most clinicians, however, have
to rely on one BMD measurement estimating the patients
fracture risk.
BMD measurement with DEXA is not universally avail-
able, is not portable, and is an imperfect predictor of future
fractures [16]. Compared to other risk factors, BMD is at
least as good in prediction of fracture as blood pressure
measurements to predict stroke and level of cholesterol
to predict cardiac infarction [23]. In addition, screening
with DEXA may not be cost-eﬀective in all groups [16].
However, available evidence indicates that neither alternative
to DEXA (non-DEXA screening tests) is suﬃciently sensitive
or speciﬁc at predicting DEXA-determined bone mass to be
recommended as a substitute for DEXA [16].
4. FractureRisk Estimation
BMD assessment, although speciﬁc, may not be sensitive
for predicting fracture risk, and therefore men with reduced
BMD may not necessarily be at an increased risk of fracture.
Adding clinical risk factors that are able to predict fracture
independent of BMD may improve our ability to predict
fracture risk. So, many osteoporosis risk-assessment tools
have been developed using risk factors with higher predictive
value [1]. For example, the Garvan fracture risk calculator
and the WHO fracture risk assessment tool (FRAX) are
useful supplements to BMD assessments, as they help
physicians to decide which patients might require prolonged
treatment to reduce the risk of future fractures [24, 25].
FRAX is an algorithm that calculates absolute fracture risk
based on population-based cohorts from Europe, North
America, Asia, and Australia. It is introduced by a WHO
task force in 2008 and estimates (calculates) the 10-year
absolute fracture risk in individual patients for hip frac-
tures or major osteoporotic fractures (hip, wrist, humerus,
and clinical spine) using femoral neck BMD (g/cm2)a n d
easily obtainable clinical risk factors for fracture [25]. The
algorithm includes the following risk factors: age, prior
fracture, parental history of hip fracture, low body weight
or BMI, use of OGCS of 5mg or more for 3 months or
more, rheumatoid arthritis (RA), current cigarette smoking,
excessive alcohol intake of 3units or more daily (3 medium
glasses of wine or 3 half pints of beer), and secondary
osteoporosis. For the FRAX tool, click on Calculation
Tool (http://www.shef.ac.uk/FRAX/), and select the country.
Based on FRAX tool, the patients with low bone mass are
separated into those with low risk versus high risk. So, men
aged50yearsandolderwithlowbonemass(T-scorebetween
−1.0and −2.5SDatthefemoralneckorspine)anda10-year
probabilityofahipfracture ≥3%ora10-yearprobabilityofa
major osteoporosis-related fracture ≥20% based on the US-
adapted WHO algorithm, are candidates for medical therapy
[25]. Although FRAX has utility as a clinical tool, it also has
multiplelimitationsthatmayaﬀectfractureriskcalculations.
Important limitations are the following [26]. (1) The BMD
input is limited to the femoral neck based on available
population data. FRAX does not account for individuals who
have low lumbar T-score but with normal femoral neck. (2)
Poordeﬁnitionofsecondaryosteoporosis.IfBMDisentered,
secondary osteoporosis does not change the calculated risk.
(3) Certain variables were excluded. For example, FRAX
does not include measurements that would be diﬃcult
to obtain by a primary care practitioner—measurements
of physical activity, vitamin D deﬁciency, bone turnover
markers, or loss of bone mass between sequential BMD
measurements. (4) FRAX does not take into account dose-
response relationships. For example, FRAX does not make a
diﬀerence between single versus multiple fractures, diﬀerent
doses and duration of glucocorticoid use, and diﬀerent doses
of units and duration of use of alcohol or smoking in terms
of packs per day. It does not take into account characteristics
f o rp r i o rf r a c t u r e ss u c ha sn u m b e r ,s e v e r i t y ,a n dt y p e .( 5 )
FRAX may only be used in untreated patients. (6) There may
be racial or ethnic diﬀerences that inﬂuence fracture risk not
taken into account by FRAX. (7) Variability in fracture rates.
Despite these limitations, FRAX is being used globally by
physicians to assess fracture risk.
Due to disruption in collagen structure, bone architec-
ture and osteocyte network, in addition to demineralization
by CS treatment, the increased fracture risk in OGCS users
seems to be mostly independent of BMD [1]. This explains
whyadjustmentsforBMDhavenotchangedsubstantiallythe
relative fracture rate in OGCS and why CS users compared
to nonusers have higher risk for vertebral fractures at the
same levels of BMD. However, bone loss due to OGCS can
be measured by BMD.
Markers of bone turnover, like C-terminal cross-linked
telopeptide of type 1 collagen or bone alkaline phosphatase,
are of uncertain clinical relevance and have not been shownISRN Rheumatology 5
to predict the risk of fracture or to correlate with changes in
BMD [1, 2, 27]. They might, however, reﬂect changes related
toantiresorptivetherapymorerapidlythanchangesinBMD.
Although these biochemical markers have contributed to
our knowledge of the pathophysiology and treatment of
osteoporosis, at this time they are not recommended in the
clinical assessment of men with osteoporosis [2].
5. Prevention and Treatment of
Osteoporosis in COPD Patients
The prevention and treatment of osteoporosis in COPD men
should be to avoid further bone loss and fragility fractures
[1, 3]. This involves nonpharmacologic and pharmacologic
measures, as lifestyle measures and nutritional recommen-
dations, management of COPD treatment (based on the use
of limited CS doses), and drug therapy (antiresorptive and
anabolic drugs).
5.1. Lifestyle Measures and Nutritional Recommendations. In
general, preventive and lifestyle modiﬁcations should be
encouraged for all COPD men to avoid bone loss. A weight-
bearing and strengthening exercise performed at least 3
times per week may be eﬀective for skeletal health given the
association of reduced physical activity with bone loss and
fracturein older men,such asthe positive eﬀectofexercisein
women with osteoporosis [1, 6]. However, a weight-bearing
and strengthening exercise cannot be performed in case of
severe COPD. In addition, smoking and excessive alcohol
intake should be avoided, while rehabilitation programs
in moderate to severe COPD, such as counselling on fall
prevention, are useful.
As a general rule, everyone COPD man with or
without diagnosed osteoporosis should receive calcium
(1000mg/day) and vitamin D (800IU/day) as a standard
supplementation, considering that calcium and vitamin
D have been shown to reduce fracture risk in men and
women (target serum level of 25-OHD ≥30ng/mL) [1, 10].
Interestingly, a dose-dependent association between vitamin
D levels and pulmonary function has been found, and
vitamin D supplement might extend beyond the protective
eﬀect on bone and inﬂuence the inﬂammation in the
lungs and interfere with comorbidities of COPD [28]. It is
recommended as a more aggressive repletion regimen when
2 5 - O H Dl e v e l sa r eb e l o w1 0n g / m L[ 10]. However, in most
cases, the addition of pharmacologic therapy is necessary for
the treatment of osteoporosis in men.
5.2. Management of COPD Treatment. The recommenda-
tions for the management of COPD treatment are mainly
based on the use of limited CS doses or reduced CS exposure
whenever possible and conclude the following [1]:
(a) long-acting bronchodilators to all patients where
airway obstruction might limit the level of physical
activity,
(b) ICS or ICS/long-acting β2a g o n i s t( L A B A )o rl o n g -
acting anticholinergics in severe COPD in order to
reduce frequency of exacerbations,
(c) maintenance therapy: ICS in moderate doses,
(d) exacerbations: consider dependent on the individual
patient:
(1) lower OGCS dose (30mg prednisolone for 7 to
8d a y s )
(2) high-dose ICS/LABA after one dose of pred-
nisolone 30mg.
5.3. Pharmacologic Therapy. Pharmacologic therapy is indi-
cated in COPD men with documented fragility hip or
vertebral (clinical or morphometric) fracture, or T-score
below −2 . 5S Do rw i t hl e s sm a r k e db o n el o s s( −1 <Ts c o r e
< −2.5) and 1 major criteria, as above mentioned [10]. The
updated National Osteoporosis Foundation (NOF) guide
basedupontheWHOfracturepredictionalgorithm(FRAX),
in conjunction with an updated US-speciﬁc economic anal-
ysis, provides also treatment recommendations for men with
osteopenia on BMD (T-score between −1.0 and −2.5SD) [6,
29]. In these individuals, the model suggests that treatment
is cost-eﬀective when the 10-year probability of hip fracture
reaches 3 percent or the 10-year probability of major
osteoporotic fracture is ≥20 percent [29]. Although these
guidelines are useful, osteoporosis treatment should remain
individualized through shared decision-making between
patient and clinician.
An oral bisphosphonate, as alendronate and risedronate,
currently considered that ﬁrst-line treatment for osteoporo-
sis in men should be recommended, with patient education
regarding potential side eﬀects [2, 5, 6, 30–32]. The main
eﬀect of bisphosphonates is the inhibition of bone resorp-
tion, but they have also been shown to prevent osteoblast
and osteocyte apoptosis and could thereby preserve the
integrity of the osteocyte network and the osteoblast lifetime
[1,33].Anumberofotherbisphosphonatesarealsoavailable
but are used less often for the treatment of osteoporosis
in men. Intravenous bisphosphonates, as zoledronic acid
(5mg once yearly), oﬀer an alternative option for men who
cannot tolerate oral bisphosphonates or who ﬁnd the dosing
regimen more convenient [6, 32].
Considering that increased bone loss starts immediately
after the beginning of OGCS treatment in a daily dose rela-
tionship and fracture risk in OGCS users seems to be mostly
independent of BMD; antiresorptive therapy in COPD
patients should be considered early during OGCS treatment.
In this regard, numerous guidelines, including those of
the Royal College of Physicians and the American College
of Rheumatology, recommend antiresorptive treatment in
corticosteroid-treated patients (>3 months) with DEXA-
deﬁned osteopenia (T score between −1a n d−2.5SD),
even in the absence of existing fragility fractures [10, 34,
35]. Vestergaard et al. recommended fracture prevention
independent of BMD status in patients reaching a yearly
cumulative dose of about 800 to 900mg prednisolone [36].
This equals 2 courses of prednisolone or a daily dose of
2.5mg prednisolone for 1 year. Bisphosphonates have been
also reported to be the most eﬀective of evaluated agents
for managing OGCS-induced osteoporosis, and this eﬀect is
enhanced further with concomitant use of vitamin D and6 ISRN Rheumatology
Table 5: Suggested approach for diagnosis and management of
male osteoporosis in COPD patients.
Initial evaluation
(i) Detailed medical history and physical examination
(ii) Documentation of height, weight, and BMI
(iii) Assessment of COPD severity
(iv) Deﬁnition of major risk factors associated with low BMD
and fractures
(v)Exclusionortreatmentofothersecondarycausesofboneloss
in men
(vi) Assessment of serum 25-OHD. Additional laboratories tests,
as suggested by results of clinical evaluation
(vii) Conﬁrmation with lateral spinal radiography of possible
vertebral fracture in patients with back pain, height loss, or
kyphosis
BMD measurement with DEXA
(i) Recommendations:
All COPD men with 3 minor (BMI < 21kg/m2, current
smoking, use of ethanol >3units/day, age > 65 years, parent hip
fracture, rib fracture, inactivity, FEV1 < 50% predicted) or 1
major [systemic corticosteroids (3 months/year), major fragility
fracture (spine-hip)]
(ii) Sites: hip and lumbar spine
(iii) Diagnostic categories of BMD according to WHO: deﬁni-
tion of osteopenia (low bone mass) as BMD T-score between
−1.0and −2.5SDanddeﬁnitionofosteoporosisasBMDT-score
≤− 2.5SD
(iv) Measurement interval:
(1) 2 years or more to follow loss or treatment eﬀect
(2) 1 year if use of OGCSs without antiresorptive therapy
Fracture risk estimation
(i) Fracture risk assessment tool (FRAX), is a useful supplement
to BMD assessments, as it helps physicians to decide which
patients might require prolonged treatment to reduce the risk
of future fractures
Prevention and treatment of osteoporosis
(i) Lifestyle measures and nutritional recommendations
(1) Smoking cessation or avoidance.
(2) Reduction of alcohol consumption, if excessive
(3) Weight-bearing and strengthening exercise
(4) Counselling on fall prevention
(5) Rehabilitation programs in moderate to severe COPD
(6) Calcium and vitamin D supplementation (1000mg and
800IU, respectively) to everyone COPD man
(ii) Management of COPD treatment based on the use of limited
CS doses.
(ii) Drug therapy
(1) Bisphosphonates
(2) Anabolic drugs (teriparatide)
OGCS: oral glucocorticosteroids; CS: corticosteroids; ICS: inhaled corticos-
teroids; BMI: body mass index; WHO: World Health Organization; FEV1:
forced expiratory volume in 1 second; FVC: forced vital capacity; COPD:
chronicobstructive pulmonary disease; BMD: bone mineral density; DEXA:
dual energy X-ray absorptiometry.
calcium. Both alendronate and risedronate are eﬀective in
thepreventionandtreatmentofOGCS-inducedosteoporosis
in both men and women, with improvements in BMD and
reduction in fracture risk [2, 5]. Men with OGCS-induced
osteoporosis treated with risedronate have fewer vertebral
fractures than those taking a placebo [2].
Anabolic drugs like the human parathyroid hormone
(PTH) analogue teriparatide (PTH 1–34) stimulate bone
formation through eﬀects on osteoblasts and osteocytes and
may therefore more directly target the main pathophysiolog-
ical mechanism in OGCS-induced osteoporosis. Teriparatide
has been found to be superior to alendronate in OGCS-
induced osteoporosis, both regarding change in BMD and
morphometric vertebral fractures, but there is no evidence
for hip fracture reduction [10, 37]. This agent is suitable
for men with severe osteoporosis (established osteoporosis;
T-scores ≤− 2.5SD in combination with at least one
fragility fracture) who continue to fracture after one year of
bisphosphonate therapy, or multiple risk factors for fracture,
orfailedprevioustreatment(thosewhocannottolerateordo
not have an adequate response to bisphosphonates) [32, 38].
Treatment should be reserved for these high-risk patients
because of the need for daily injection and high cost; there
a r en or e a lc o n c e r n sa b o u to s t e o s a r c o m ar i s k[ 1, 6] with the
use of teriparatide in men. Based upon several trials, which
have reported that PTH plus alendronate (either started
concurrently or prior to PTH) resulted in no additional
beneﬁt for spine or hip BMD compared with PTH alone, we
do not recommend concurrent use of bisphosphonates with
teriparatide for the management of male osteoporosis.
Monitoring the response to therapy is important for
identifying patients who may require a change in therapy.
Treatment failure is said to have taken place when there are
further fragility fractures despite adherence to treatment for
one year and/or BMD declines below pretreatment baseline.
While there are a number of approaches to monitoring
therapy, there is no consensus on the optimal approach.
To conﬁrm treatment response, one repeat DEXA scan is
usually recommended after a minimum of two years of
treatment, as it takes this long for response to antiresorptive
agents to exceed the least signiﬁcant change in BMD [25].
Furthermore, the BMD may fall in the ﬁrst year of treatment
only to subsequently gain in the second year a phenomenon
known as regression to the mean [27]. The use of BMD
has the disadvantages of taking two years before a lack of
response will be noted, and also the spine can be aﬀected by
degenerative changes, especially in patients over 65 years. So,
osteophytes and vascular calciﬁcations on the spine might
be a limitation to the use of spine DEXA in aging men.
The BMD measurement interval in OGCS patients without
antiresorptive treatment is recommended being one year
[1].
An alternative to BMD measurement for monitoring
therapy is to use bone turnover markers, which have a
maximum suppression in the order of 50% within three
months of starting therapy [27]. These markers tend to be
very variable and inﬂuenced by many factors. Moreover, its
usetomonitorresponsetotherapyisnotwellstudiedinmen
and is not routinely recommended [27].ISRN Rheumatology 7
A suggested approach for diagnosis and management of
male osteoporosis in COPD patients is presented in Table 5.
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